Dexpramipexole was well tolerated, and had a favorable safety profile.

Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with ...

Biologics targeting type 2 inflammation show strong efficacy in eosinophilic COPD, while non-type 2 approaches remain ...

Three years on from a splashy unveiling, Areteia Therapeutics has reported a phase 3 victory that could boost its bid to launch an oral rival to the biologics that dominate a multibillion-dollar ...

The RESOLUTE phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic ...

Some people with very severe asthma symptoms have a condition called eosinophilic asthma. People with this type of asthma may need to use inhaled medicines along with a newer type of medicine that is ...

Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...

AstraZeneca (NASDAQ:AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering from ...

Privately-held Areteia Therapeutics has announced positive results from the Phase III EXHALE-4 efficacy and safety study of ...

Taking antibiotics while ill with the flu may increase the risk of developing bacterial pneumonia, according to new findings from researchers at Los Angeles-based Cedars-Sinai. Researchers found that ...

STATEN ISLAND, N.Y. — Taking antibiotics during an influenza infection can increases the risk of developing a dangerous bacterial pneumonia, according to recent research. Antibiotics are often ...